NDC 67184-1007-01 - Ceftriaxone Sodium
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 67184-1007
- Requested NDC
- 67184-1007-01
- Package NDCs from labels
- 67184-1007-1, 67184-1007-01
- Manufacturer
- Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical Co., Ltd.(High Tech Zone Site) | Qilu Antibiotics Pharmaceutical Co., Ltd.
- Effective date
- 2026-02-04
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Ceftriaxone for Injection, USP | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical Co., Ltd.(High Tech Zone Site) | Qilu Antibiotics Pharmaceutical Co., Ltd. | 2026-02-04 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67184-1007-1 | Ceftriaxone Sodium | 1 in 1 VIAL, SINGLE-USE | INJECTION, POWDER, FOR SOLUTION | 1 | 4 | |
| 67184-1007-1 | Ceftriaxone Sodium | 10 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 10 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 67184-1007 | CEFTRIAXONE SODIUM INJECTION, POWDER, FOR SOLUTION [QILU PHARMACEUTICAL CO., LTD.] | 2 | Current NDC, Legacy NDC, 2 package rows | 20181121_4cdf0743-c62b-4969-b9c9-4c6400644f6c.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | 1aa0a4ee-1b39-4c3d-a7a3-33dded6fe28c | 2024-01-31 | Warnings, Adverse reactions | 309092 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | ff8e830a-c288-46fb-9e19-ec2017943c07 | 2024-01-31 | Warnings, Adverse reactions | 309092 023Z5BR09K |
| ceftriaxone | CEFTRIAXONE | Sagent Pharmaceuticals | 5cf93bc5-9e4c-4734-bc02-c7d0ac071022 | 2023-11-08 | Warnings, Adverse reactions | 1665046 1665005 1665021 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE | Fresenius Kabi USA, LLC | 7ea1db43-40fa-417b-8911-ae98092070a0 | 2023-09-30 | Warnings, Adverse reactions | 1665046 1665005 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Asclemed USA, Inc. | f01cf0e5-caaf-4759-ba21-50f3aceff523 | 2023-09-02 | Warnings, Adverse reactions | ANDA203702 1665005 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Apotex Corp. | 5116231f-82d1-44be-b08e-560c9a50e5c5 | 2023-08-31 | Warnings, Adverse reactions | ANDA203702 1665046 1665005 309092 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Apotex Corp. | ac03a72c-0e35-40f9-b7fc-081badb5f19c | 2023-01-28 | Warnings, Adverse reactions | 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE SODIUM | Samson Medical Technologies, LLC | 5cd2d96f-83e5-4326-ae87-d0ede4ba493a | 2023-01-15 | Warnings, Adverse reactions | 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE | Proficient Rx LP | fcf401df-bcdc-4773-a63b-9741c0f74b3d | 2022-11-01 | Warnings, Adverse reactions | 1665046 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Proficient Rx LP | a25ab5ea-c46d-4562-8f7e-0ccffc2ab069 | 2022-10-01 | Warnings, Adverse reactions | 1665046 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Proficient Rx LP | 42ba7a9d-7d2b-4eac-af59-897151a8c924 | 2022-05-02 | Warnings, Adverse reactions | ANDA203702 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 9d1f630b-e759-4395-9d01-ddc90e4fea75 | 2022-03-09 | Warnings, Adverse reactions | 1665046 1665021 023Z5BR09K |
| CEFTRIAXONE AND DEXTROSE | CEFTRIAXONE | B. Braun Medical Inc. | 67153914-16bc-490d-82d7-638061618467 | 2022-01-13 | Warnings, Adverse reactions | 1665046 1665021 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE | Hikma Pharmaceuticals USA Inc. | 8351aa37-552d-471d-b293-c564dcb6ec29 | 2021-12-01 | Warnings, Adverse reactions | 1665046 1665005 309092 1665021 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE | Hikma Pharmaceuticals USA Inc. | 1f8776bd-4f5b-427a-849a-6b8338f7997d | 2019-04-24 | Warnings, Adverse reactions | 023Z5BR09K |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.